Oncotarget

Research Papers:

Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer

Andreas W. Berger, Daniel Schwerdel, Thomas J. Ettrich, Alexander Hann, Stefan A. Schmidt, Alexander Kleger, Ralf Marienfeld and Thomas Seufferlein _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:2076-2085. https://doi.org/10.18632/oncotarget.23330

Metrics: PDF 664 views  |   HTML 922 views  |   ?  


Abstract

Andreas W. Berger1, Daniel Schwerdel1, Thomas J. Ettrich1, Alexander Hann1, Stefan A. Schmidt2, Alexander Kleger1, Ralf Marienfeld3,* and Thomas Seufferlein1,*

1Department of Internal Medicine I, Ulm University, 89081 Ulm, Germany

2Department of Diagnostic and Interventional Radiology, Ulm University, 89081 Ulm, Germany

3Institute of Pathology, Ulm University, 89070 Ulm, Germany

*These authors contributed equally to this work

Correspondence to:

Thomas Seufferlein, email: Thomas.seufferlein@uniklinik-ulm.de

Keywords: circulating tumor DNA; liquid biopsy; pancreatic cancer; tumor evolution; tumor heterogeneity

Received: April 25, 2017     Accepted: December 08, 2017     Published: December 16, 2017

ABSTRACT

Purpose: Precision medicine in pancreatic ductal adenocarcinoma (PDAC) could be substantially supported by tools that allow to establish and monitor the molecular setup of the tumor. In particular, noninvasive approaches are desirable, but not validated. Characterization of circulating tumor DNA (ctDNA) may help to achieve this goal.

Experimental Design: Blood samples from patients with metastatic PDAC prior to and during palliative treatment were collected. ctDNA and corresponding tumor tissue were analyzed by targeted next generation sequencing and droplet digital PCR for the 7 most frequently mutated genes in PDAC (TP53, SMAD4, CDKN2A, KRAS, APC, ATM, and FBXW7). Findings were correlated with clinical and imaging data.

Results: A total of 20 patients (therapy naïve n = 11; pretreated n = 9) were included. All therapy naïve patients (n = 11/11) presented with detectable ctDNA at baseline. In pretreated patients, 3/7 (prior to 2nd line treatment) and 2/2 (prior to 3rd line chemotherapy) had detectable ctDNA. The combined mutational allele frequency (CMAF) of KRAS and TP53 was chosen to reflect the amount of ctDNA. The median CMAF level significantly decreased during treatment (P = 0.0027) and increased at progression (P = 0.0104). CA19-9 analyses did not show significant differences. In treatment naïve patients, the CMAF levels during therapy significantly correlated with progression-free survival (Spearman, r = −0.8609, P = 0.0013).

Conclusions: Monitoring of ctDNA and its changes during treatment may enable to adapt therapeutic strategies to the specific molecular changes present at a certain time during treatment of mPDAC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23330